CRISPR Gene Editing (2012)

CRISPR-Cas9's 2012 adaptation by Jennifer Doudna and Emmanuelle Charpentier, which won the 2020 Nobel Prize in Chemistry, is the fastest-advancing gene-editing tool in history: over 50 clinical trials were underway by 2024, double the number for any prior gene therapy technique at the same stage. This programmable system, derived from a bacterial immune defense, enables precise editing of any genome in living cells, revolutionizing genetic disease treatment, crop engineering, and medical research. It outperforms all previous gene-editing methods in speed, cost, and accuracy, making it the foundational tool of genomic medicine — potentially reversing hereditary conditions and creating disease-resistant organisms.